1-3 of 3
Keywords: Myelosuppression
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1977) 34 (1): 45–46.
Published Online: 09 June 2009
... the average of three previously reported disease-oriented phase II trials, though the difference was not significant statistically. The time course of myelosuppression seemed comparable to that seen with a single dose schedule of administration. 9 6 2009 © 1977 S. Karger AG, Basel 1977...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2009) 76 (4): 231–238.
Published Online: 25 February 2009
... from any ideas, methods, instructions or products referred to in the content or advertisements. Oxaliplatin Hypersensitivity Neurotoxicity Myelosuppression Table 2 Hypersensitivity reactions to oxaliplatin 2002–2007 The major adverse events associated with oxaliplatin consist...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (Suppl. 1): 42–46.
Published Online: 26 September 2001
... patients. Patients received a median of 5 courses of oral topotecan. Grade 3/4 myelosuppression was common in patients treated with 2.0 mg/m 2 ; secondary to 2 patients developing fatal sepsis, patients enrolled later in the study were treated at 1.7 mg/m 2 . At both doses, the majority of nonhematologic...